Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (NYSE: DGX) announced that Chairman, CEO and President Jim Davis will deliver a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago. The presentation is scheduled for June 3, 2025, at 11:00 a.m. Eastern Time.

During the presentation, Davis will discuss the company's strategy, performance, and current market trends. Investors can access the live webcast through Quest's investor relations page at ir.QuestDiagnostics.com. The archived version will be available within 24 hours after the event and remain accessible until July 3, 2025.

Quest Diagnostics (NYSE: DGX), a leading diagnostic information services provider, has announced a quarterly cash dividend of $0.80 per share. The dividend will be paid on July 21, 2025, to shareholders who are on record as of July 7, 2025. This regular dividend declaration demonstrates Quest's commitment to providing consistent returns to its shareholders.

Quest Diagnostics (NYSE: DGX) reported strong Q1 2025 financial results with revenues of $2.65 billion, up 12.1% from 2024. The company achieved reported diluted EPS of $1.94 (up 12.8%) and adjusted diluted EPS of $2.21 (up 8.3%).

Key performance metrics include:

• Diagnostic Information Services revenues increased 12.7% to $2.59 billion
• Operating income rose 15.4% to $346 million
• Net income grew 13.2% to $220 million
• Cash from operations doubled to $314 million

Quest reaffirmed its full-year 2025 guidance with:

• Expected revenues between $10.70-10.85 billion
• Projected revenue growth of 8.4-9.9%
• Updated reported diluted EPS guidance of $8.62-8.87
• Maintained adjusted diluted EPS guidance of $9.55-9.80

Quest Diagnostics (NYSE: DGX) has launched AD-Detect™, a new laboratory blood test designed to confirm amyloid brain pathology in Alzheimer's disease patients with mild cognitive impairment or dementia. The test combines blood levels of amyloid beta 42/40 and p-tau217 to produce the AD-Detect Likelihood Score™.

Research presented at the 2025 AAN Annual Meeting demonstrated the test's 91% sensitivity and specificity, with positive and negative predictive values of 89% in mild cognitive impairment populations. The test showed strong performance in real-world specimens, categorizing 42% as high likelihood, 51% as low likelihood, and 7% as indeterminate for PET positivity.

The test is now available nationwide (except New York) through Quest's network of approximately 8,000 patient access points. This blood-based test offers a more affordable and less invasive alternative to traditional amyloid PET imaging and cerebral spinal fluid testing.

Quest Diagnostics (NYSE: DGX) has launched a new FDA-cleared HPV self-collection solution for cervical cancer screening. The service allows patients to collect their own specimens in healthcare settings and will be available at Quest's 2,000 patient service centers starting next month.

The solution utilizes Roche's FDA-cleared HPV self-collection technology, approved for use with their cobas® HPV test in May 2024. This initiative follows Quest's successful launch of self-collection services for STIs in October 2024.

The self-collection option comes at no extra charge and aims to address the declining screening rates, with 4.4 million fewer American women receiving screenings in 2021 compared to 2019. The service is not FDA approved for at-home collection and is not intended to replace regular pelvic examinations.

Quest Diagnostics (NYSE: DGX) has scheduled the release of its first quarter 2025 financial results for Tuesday, April 22, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results.

Participants can join the call by dialing 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) using passcode '7895081'. The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until May 6, 2025, via the website or by phone at 866-361-4757 (domestic) or 203-369-0183 (international).

Quest Diagnostics (NYSE: DGX) outlined its strategic vision at its 2025 Investor Day, projecting 4-5% compound annual revenue growth and 7-9% adjusted EPS growth beyond 2025. The company's growth strategy focuses on expanding market access in physician and hospital channels, achieving double-digit growth in advanced diagnostics across five key clinical areas, and leveraging strategic partnerships.

Key initiatives include driving growth through diagnostic innovation, expanding hospital collaborative lab solutions, growing consumer-initiated testing via questhealth.com, and focusing on advanced diagnostics in oncology, cardiometabolic health, women's health, brain health, and autoimmune disorders. The company aims to achieve 3% annual productivity savings through its Invigorate initiative and modernize IT systems through Project Nova.

For Q1 2025, Quest expects weather-related impacts to create a $25 million revenue headwind and approximately $0.10 EPS impact.